Open AccessPatients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer
Author(s) -
Rebecca L. Stone,
M. Janelle CambronMellott,
Kathleen Beusterien,
Martine C. Maculaitis,
Stephanie Ritz,
Emily Mulvihill,
Matthew J. Monberg,
Elizabeth A. Szamreta,
Suvina Amin,
Kimmie McLaurin
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0567
Subject(s) - medicine , ovarian cancer , maintenance therapy , oncology , adverse effect , parp inhibitor , dosing , cancer , chemotherapy , poly adp ribose polymerase , biochemistry , chemistry , polymerase , gene
Aim: To understand the preferences of US patients and oncologists for PARP inhibitors as second-line maintenance (2LM) for epithelial ovarian cancer. Methods: A discrete choice experiment was conducted to assess the preferences of treatment attributes. Results: The most valued attributes were risk of grade 3/4 adverse events (AEs; patients, n = 204) and progression-free survival (PFS; oncologists, n = 151). To accept a 37% increased risk of grade 3/4 AEs, PFS would need to increase by 27.9 months (patients) and 6.3 months (oncologists). The least valued attributes were dosing form/frequency (patients) and grade 3/4 anemia risk (oncologists). Conclusion: Patients' and oncologists' willingness to make benefit–risk trade-offs in the 2LM setting suggests that the PFS gains observed in selected studies of poly (ADP-ribose) polymerase inhibitors in BRCA-mutated disease are worth the toxicity risk.